Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): A parallel-group, double-blind randomised phase 4 trial

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 2, 2016, Pages 136-147

  Brown, Morris J ^a   Williams, Bryan ^b,c   Morant, Steve V ^d   Webb, David J ^e   Caulfield, Mark J ^f   Cruickshank, J Kennedy ^g   Ford, Ian ^h   McInnes, Gordon ⁱ   Sever, Peter ^j   Salsbury, Jackie ^a   Mackenzie, Isla S ^d   Padmanabhan, Sandosh ⁱ   MacDonald, Thomas M ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; RENIN INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; MUSCLE SPASM; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HEALTH CARE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED KINGDOM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED;

AGED; AMILORIDE; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84958034353     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00377-0     Document Type: Article

References (39)

1. Brown MJ The choice of diuretic in hypertension: saving the baby from the bathwater. Heart 2011, 97:1547-1551.
2. Messerli FH, Bangalore S Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011, 124:896-899.
3. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
4. Cutler JA Thiazide-Associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?. Hypertension 2006, 48:198-200.
5. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet 1982, 320:1293-1295.
6. Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension 2008, 52:30-36.
7. Manrique C, Johnson M, Sowers JR Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension 2010, 55:15-17.
8. Duarte JD, Cooper-DeHoff RM Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010, 8:793-802.
9. Mackenzie IS, Brown MJ Molecular and clinical investigations in patients with low- renin hypertension. Clin Exp Nephrol 2009, 13:1-8.
10. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
11. Girvin B, Johnston GD A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998, 16:1049-1054.
12. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990, 300:975-978.
13. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with once-daily calcium channel blockade or diuretic in the INTERNATIONAL Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000, 356:366-442.
14. Hood SJ, Taylor KP, Ashby MJ, Brown MJ The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007, 116:268-275.
15. Mancia G, Grassi G, Zanchetti A New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3-10.
16. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005, 23:1777-1781.
17. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412. Medical Research Council Working Party.
18. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006, 29:2592-2597.
19. Stears A, Woods S, Watts M, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension 2012, 59:939-942.
20. Hood SJ, Picton DE, Taylor KP, Brown MJ Value of routine plasma renin assay in the detection, treatment-titration or cure of low-renin patients with salt-dependent hypertension. J Human Hypertension 2009, 23:693.
21. Brown MJ, Williams B, MacDonald TM, et al. Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. BMJ Open 2015, 5:e008086.
22. Morganti A A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. J Hypertens 2010, 28:1307-1312. European study group for the validation of DiaSorin Liaison Direct Renin Assay.
23. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
24. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975. ALLHAT Collaborative Research Group.
25. Thomas JP, Thomson WH Comparison of thiazides and amiloride in treatment of moderate hypertension. BMJ (Clin Res Ed) 1983, 286:2015-2018.
26. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007, 167:1068-1074.
27. Stern MP, Williams K, Haffner SM Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?. Ann Intern Med 2002, 136:575-581.
28. McNeely MJ, Boyko EJ, Leonetti DL, Kahn SE, Fujimoto WY Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care 2003, 26:758-763.
29. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397-405. Decode Study Group, on behalf of the European Diabetes Epidemiology Groupon behalf of the European Diabetes Epidemiology Group.
30. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980, 1:1373-1376.
31. Burton TJ, Mackenzie IS, Balan K, et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2012, 97:100-109.
32. Hughes AD How do thiazide and thiazide-like diuretics lower blood pressure?. J Renin Angiotensin Aldosterone Syst 2004, 5:155-160.
33. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000, 342:905-912. the Atherosclerosis Risk in Communities Study.
34. Elliott WJ, Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
35. McMurray JJ, Holman RR, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477-1490. NAVIGATOR Study Group.
36. 1c as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010, 6:589-593.
37. Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008, 51:762-768.
38. Hypertension (update): full guideline National Institute for Health and Care Excellence, (accessed Oct 4, 2015). https://www.nice.org.uk/guidance/cg127/evidence/cg127-hypertension-full-guideline3.
39. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015, published online Sept 21. 10.1016/S0140-6736(15)00257-3.